Oxford Immunotec Global PLC (OXFD) Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 8.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,631 shares of the company’s stock after purchasing an additional 1,500 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.08% of Oxford Immunotec Global worth $313,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in OXFD. Voya Investment Management LLC grew its stake in Oxford Immunotec Global by 16.0% in the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after purchasing an additional 1,845 shares in the last quarter. Alliancebernstein L.P. bought a new position in Oxford Immunotec Global in the second quarter worth approximately $247,000. Rhumbline Advisers grew its stake in Oxford Immunotec Global by 9.1% in the second quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock worth $412,000 after purchasing an additional 2,053 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Oxford Immunotec Global by 175.0% in the first quarter. Goldman Sachs Group Inc. now owns 35,678 shares of the company’s stock worth $553,000 after purchasing an additional 22,704 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in Oxford Immunotec Global by 15.7% during the 1st quarter. Teachers Advisors LLC now owns 46,200 shares of the company’s stock valued at $716,000 after acquiring an additional 6,268 shares in the last quarter. 89.35% of the stock is currently owned by institutional investors.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at $14.88 on Monday. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.38. Oxford Immunotec Global PLC has a 52-week low of $12.19 and a 52-week high of $19.51.

OXFD has been the topic of several recent research reports. Piper Jaffray Companies dropped their target price on Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 31st. Zacks Investment Research cut Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Saturday, November 4th. Robert W. Baird reaffirmed a “buy” rating and set a $20.00 target price on shares of Oxford Immunotec Global in a research report on Wednesday, November 1st. ValuEngine cut Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Finally, BTIG Research set a $21.00 target price on Oxford Immunotec Global and gave the company a “buy” rating in a research report on Tuesday, October 31st. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. Oxford Immunotec Global presently has a consensus rating of “Hold” and an average target price of $19.75.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the sale, the director now owns 17,778 shares of the company’s stock, valued at approximately $237,336.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. 8.11% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Oxford Immunotec Global PLC (OXFD) Shares Bought by The Manufacturers Life Insurance Company” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/12/04/oxford-immunotec-global-plc-oxfd-shares-bought-by-the-manufacturers-life-insurance-company.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

What are top analysts saying about Oxford Immunotec Global PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oxford Immunotec Global PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit